CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine could shield transplant patients from deadly virus
⭐️ VACCINE ⭐️ OngoingThis study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 05:35 UTC
-
New vaccine aims to shield transplant patients from deadly virus
⭐️ VACCINE ⭐️ OngoingThis study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:05 UTC
-
New combo aims to wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding pembrolizumab (an immunotherapy) to standard tyrosine kinase inhibitors (TKIs) can eliminate leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with stable disease but detectable cancer markers will receive the c…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New drug combo shows promise in controlling Early-Stage leukemia
Disease control OngoingThis study tests whether combining two drugs, dasatinib and venetoclax, can better control early chronic phase chronic myeloid leukemia (CML). About 155 adults with a specific genetic marker (Philadelphia chromosome or BCR-ABL1 positive) who have had little or no prior treatment …
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy aims to squash stubborn leukemia cells
Disease control OngoingThis study tests whether adding ruxolitinib to standard CML medications (like dasatinib or nilotinib) can further reduce the number of leukemia cells in patients who still have detectable disease. About 81 adults with chronic-phase CML will receive either their usual drug alone o…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 13, 2026 15:58 UTC